To determine if PEITC inhibits the growth of prostate cancer cells expressing different hotspot p53 mutants and restores transactivation functions, we treated human prostate LAPC-4 (p53R175H) (structural mutant) and VCaP (p53R248W) (contact mutant) cells, that are homozygous p53 mutant, with PEITC. The gene discussed is TP53; the disease is prostate carcinoma.